Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue was more effective in reducing HbA1c and weight in patients compared to MSD’s Januvia (sitagliptin) and its own best-selling inje